76
Participants
Start Date
October 31, 2014
Primary Completion Date
March 23, 2018
Study Completion Date
November 12, 2018
Fostamatinib 150 mg
Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg
Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Placebo
Placebo tablet twice daily by mouth, over the course of 24 weeks
School of Medicine, Chang Gung University, Chang Gung Memorial Hospital, Taoyuan District
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
Medical University of Graz, Graz
Nephrology Associates PC, University Hospital, Professional Center 1, Augusta
Southeast Renal Research Institute, Chattanooga
China Medical University Hospital, Taichung
Ohio State University, Columbus
Medical University of Heidelberg, Heidelberg
Klinikum der Universität München, Munich
Stanford University Medical, Palo Alto
Medical University Vienna, Nephrology, Vienna
Medical University of Jena, Jena
Prince of Wales Hospital, Hong Kong
Queen Mary Hospital, Hong Kong
Addenbrookes Hospital, Cambridge
Cardiff University, Cardiff
Leicester General Hospital, Leicester
Royal Free Hospital, London
Hammersmith Hospital, London
Freeman Hospital, Newcastle upon Tyne
Lead Sponsor
Rigel Pharmaceuticals
INDUSTRY